Non-Pharmacologic Therapies for Atopic Dermatitis

Clinical Dermatology & Pediatrics, Northwestern University Feinberg School of Medicine, 1455 N. Milwaukee Ave, 2nd Floor, Chicago, IL, 60622, USA, .
Current Allergy and Asthma Reports (Impact Factor: 2.77). 07/2013; 13(5). DOI: 10.1007/s11882-013-0371-y
Source: PubMed


Atopic dermatitis (AD) continues to present significant therapeutic challenges, especially in severe cases. Navigating the line between risk and benefit can be difficult for more powerful medications such as immunosuppressants, but non-pharmacologic treatments are often overlooked and underutilized. Creative application of these more physical therapies can serve to minimize the pharmacologic treatments and their side effects, and possibly even create synergy between modalities, to maximize benefit to the patient.

25 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin condition affecting approximately 25% of children and 3% of adults. Atopic dermatitis has a major impact on the quality of life of both patients and their families, and this impact may be even more significant than that of many other chronic diseases. Atopic dermatitis is not curable, and constant care and therapy are necessary in order to control the disease. Although numerous medications that treat AD effectively are available, they have a considerable side effect profile and cost implications. Therefore, the management of AD with safer and potentially more cost-effective non-pharmacologic treatment options needs attention. This article is not a comprehensive review of all of the non-pharmacologic measures available for treating AD, but includes the most practical and important options. Occlusive dressings, including the use of “wet wraps”, correct bathing practices, the use of antiseptics and antimicrobials, laundry practices, choice of clothing, phototherapy, appropriate use of emollients, psychological measures as well as the education of patients will be discussed. Some of these non-pharmacological treatment options (emollients, correct bathing practices, education) form the cornerstones of AD treatment. Unfortunately, although these treatment options are very effective and widely used, robust data supporting their efficacy and cost-effectiveness is not readily available. Further research in this field should be encouraged, especially in the South African setting.
    Current Allergy and Clinical Immunology 06/2014; 27(2):88-93. · 0.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis is a common skin disease characterized by eczematous eruptions and impaired skin barrier function. Patients, as well as their families, frequently report reductions in quality of life. Pruritus, lack of sleep, and impaired social functioning all contribute to this reduction. A skincare regimen of gentle cleansing and daily moisturization is integral to managing atopic dermatitis. While there are a multitude of reports supporting the use of moisturizers, there is a paucity regarding the use of cleansers, especially cleansers formulated with ingredients known to improve skin hydration. A clinical study was conducted to assess the tolerability and cosmetic acceptability of a body wash formulated with the filaggrin break-down products arginine and pyrrolidone carboxylic acid in subjects with atopic dermatitis-prone skin (Cetaphil® RestoraDerm® Body Wash). The results of this study indicate that Cetaphil RestoraDerm Body Wash was well tolerated, reduced itch, improved quality of life, and was well-liked by subjects with atopic dermatitis-prone skin. J Drugs Dermatol. 2014;13(9):1108-1111.
    Journal of drugs in dermatology: JDD 09/2014; 13(9):1108-1111. · 1.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis and atopic dermatitis are non-contagious inflammatory skin diseases with a chronic and relapsing course. Currently, although several treatments are available to control these disorders, other therapies are under investigation. The available therapies help relieve the symptoms and increase the time between flare-ups. However, due to the chronic course of these diseases, becoming refractory to long-term treatment is often a possibility. AN-2728 is an investigational drug targeting the inflammatory pathway. It is a novel boron-containing molecule that inhibits the release of proinflammatory cytokines by binding to the active water in the bimetal center of the active site of the phosphodiesterase PDE4 enzyme. AN-2728 has shown a promising safety profile and is generally well tolerated following topical application in patients with mild to moderate psoriasis and atopic dermatitis. In several phase II studies, the primary endpoint has been successfully achieved. Copyright © 2014 Prous Science, S.A.U. or its licensors. All rights reserved.
    Drugs of the Future 09/2014; 39(9):607. DOI:10.1358/dof.2014.039.09.2182240 · 0.17 Impact Factor